REG - ReNeuron Group plc - Notification of Interim Results <Origin Href="QuoteRef">RQE.L</Origin>

ReNeuronAnnouncement

12/11/2015 14:41

RNS Number : 5422F
ReNeuron Group plc
12 November 2015
12 November 2015
AIM: RENE
ReNeuron Group plc
("ReNeuron" or "the Company")
Notification of Interim Results
Guildford, UK, 12 November 2015: ReNeuron Group plc (AIM: RENE), a leading UK-based stem cell therapy company, will announce its interim results for the six months ended 30 September 2015 on Monday 7 December 2015.
A meeting for analysts will be held at 9.30am on the morning of the results announcement at the offices of Buchanan, 107 Cheapside, London EC2V 6DN. 
For a webcast of the analyst presentation, please log on to the following web address approximately 10 minutes before 9.30am on the day of the results: http://vm.buchanan.uk.com/2015/reneuron071215/registration.htm
A recording of the presentation will be made available on ReNeuron's and Buchanan's websites, www.reneuron.com and www.buchanan.uk.com
Enquiries:
ReNeuron
 +44 (0) 1483 302560
Olav Helleb , Chief Executive Officer

Michael Hunt, Chief Financial Officer

Buchanan
+44 (0) 20 7466 5000
Mark Court, Sophie Cowles, Stephanie Watson



Cenkos Securities
+44 (0) 20 7397 8900
Stephen Keys, Dr Christopher Golden (NOMAD and Broker)

Russell Kerr (Sales)

About ReNeuron
ReNeuron is a leading, clinical-stage cell therapy development business. Based in the UK, its primary objective is the development of novel cell-based therapies targeting areas of significant unmet or poorly met medical need. 
ReNeuron has used its unique stem cell technologies to develop cell-based therapies for significant disease conditions where the cells can be readily administered "off-the-shelf" to any eligible patient without the need for additional immunosuppressive drug treatments. The Company's therapeutic candidates for stroke disability and critical limb ischaemia are in clinical development and its cell-based treatment for the blindness-causing disease, retinitis pigmentosa, is about to enter the clinic in the US. 
ReNeuron is also advancing a proprietary platform technology to exploit nanoparticles (exosomes) secreted by stem cells as potential new drug candidates targeting a range of cancers.
ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. Further information on ReNeuron and its products can be found at www.reneuron.com.

This information is provided by RNS
The company news service from the London Stock Exchange
  END
NOREALFAFLESFFF